Financial Shenanigans

Financial Shenanigans Assessment

Overall forensic risk: MODERATE-HIGH. Not because of earnings manipulation — the numbers look genuinely bad. The risk centers on the VIE structure, related-party dynamics with Daqo Group, the opacity of the subsidiary cash flow, and the question of whether reported liquid assets are truly accessible to ADS holders.

Breeding Ground Assessment

No Results

Earnings Manipulation Tests

Revenue Recognition — LOW RISK

Polysilicon sales are straightforward commodity transactions: physical delivery of product at spot or contracted prices. There is minimal scope for revenue manipulation because:

  • Revenue = kilograms sold x price per kg (publicly benchmarkable)
  • No multi-element arrangements, subscription models, or percentage-of-completion
  • No long-term contracts that create deferred revenue complexity
  • Sales volumes and pricing are reported quarterly and verifiable against industry data

Test: DSO trend

Loading...

DSO spiked to 75 days in FY2025 from 20 days in FY2024. In isolation this would be concerning, but in context: Daqo dramatically reduced sales volume in Q4 2025 (38K MT vs 42K MT in Q3) while maintaining production, meaning receivables reflect a higher proportion of late-quarter sales. The Q1 2026 decision to sell only 4,482 MT (10% of production) confirms management is deliberately holding inventory rather than selling at below-cost prices. This is consistent behavior, not manipulation.

Expense Shifting — LOW RISK

Loading...

D&A rose from $69M (2020) to $240M (2025) as Baotou expansion assets came online. At 36% of revenue, this is extremely high but reflects real asset additions, not accounting choice. No evidence of useful-life extensions or capitalization of operating costs.

One-Time Items — MODERATE CONCERN

The Q1 2026 inventory impairment of $98.4M is large but directionally appropriate — polysilicon prices fell below production cost. The concern: will management take a "big bath" to reset the earnings baseline? Given that a new cost model from MIIT is expected mid-2026, there's a risk that management front-loads impairments before the policy change, creating an easier comparison going forward.

Cash Flow Manipulation Tests

Operating CF vs Net Income

Loading...

Cash conversion has been generally healthy. FY2025 OCF of $50M vs net loss of $216M is consistent with expectations — D&A adds back ~$240M, and working capital changes contributed positively. No evidence of factoring, securitization, or non-standard OCF enhancement.

Capex Classification — CLEAN

Capex aligns with disclosed Baotou expansion project. The decline from $1.2B (2022) to $173M (2025) matches project progress. No evidence of operating expenses being capitalized.

Key-Metric Manipulation Tests

Non-GAAP Concerns — MODERATE

Management reports non-GAAP EBITDA that excludes SBC. Given SBC of $56M in FY2025 (on a $665M revenue base), this exclusion is material. EBITDA of $1.7M becomes -$54M after SBC. However, this practice is standard in the industry and consistently disclosed.

Subsidiary Cash Trap Risk — HIGH

No Results

Forensic Scorecard

No Results

Bottom Line

The reported financial statements appear to faithfully represent a business in genuine distress. There is no evidence of earnings inflation, revenue fabrication, or cash flow manipulation. The forensic risk is structural, not behavioral: the VIE architecture, subsidiary cash trapping, and controlling shareholder dynamics create a situation where reported book value and cash balances may significantly overstate the value accessible to outside shareholders. This is not a fraud flag — it is a governance and structure discount that the market is clearly applying at 0.26x book value.